Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07364734Recruiting

Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease

Role: lead

NCT06912815Not ApplicableRecruiting

Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.

Role: lead

NCT06780683Recruiting

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Role: lead

All 3 trials loaded